VIMTA LABS LTD.-$ - 524394 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation in term of regulation 39(3) - Issue of duplicate share certificate.24-05-2024
24-05-2024
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meet.24-05-2024
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Q4 - 2024 earnings/investor call held on 21st May 2024.21-05-2024
Vimta Labs Results Earnings Call for Q4FY24
Conference Call with Vimta Labs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.21-05-2024
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Audited Standalone and Consolidated Financial Results for the 4th Quarter and financial year ended 31st March, 2024, published in Financial Express (English) and Andhra Prabha (Telugu) on 20th May, 2024.20-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Vimta Labs Ltd.
Healthcare Services company Vimta Labs announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total Income for Q4FY24 was at Rs 802 million EBITDA for Q4FY24 was Rs 249 million; EBITDA margin was at 31.1% Q4FY24 PAT was at Rs 124 million Basic EPS in Q4FY24 was Rs 5.6 FY24 Financial Highlights: Total Income for FY24 was at Rs 3,223 million EBITDA for FY24 was Rs 908 million; EBITDA margins at 28.2% FY24 PAT was at Rs 410 million Basic EPS was Rs 18.5 in FY24 Cash flow From Operations at Rs 609 million for FY24; FY24 Capex at Rs 763 million Cash and Cash equivalents at Rs 258 million as of 31st March 2024 Debt to Equity ratio 0.06x Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs Limited, said: “Q4 maintained good recovery after H1 being harsh on us. Having a strong and resilient business model has helped us strive through some headwinds and get back to the historical figures. Our services to the Pharmaceutical industry have seen a promising uptick, demonstrating growth in both pre-clinical and analytical services. We have recently expanded our offerings to include clinical trials, which we anticipate will be a major driver of future growth. The Food segment experienced initial setbacks due to supply chain disruptions caused by various external factors. However, this segment has begun to recover and shows promise for continued improvement. Our new Electronics and Electrical testing division delivered strong results, while our other segments have gone through some corrections in services and their scale. Looking forward, we are confident in our ability to achieve significant growth. While FY24 presented unforeseen challenges, we are optimistic that FY25 will be a year of robust expansion for the company.” Result PDF20-05-2024
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation - Q4 Results - FY 2023-2418-05-2024
VIMTA LABS LTD.-$ - 524394 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Vimta Labs Limited Reports Q4 & FY24 Results.18-05-2024
VIMTA LABS LTD.-$ - 524394 - Corporate Action-Board approves Dividend
Recommendation of Dividend.18-05-2024
VIMTA LABS LTD.-$ - 524394 - Results - Financial Results 31.03.2024.
Audited standalone and consolidated financial results for the 4th quarter ended and year ended 31.03.2024.18-05-2024